Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289361 | 0.85 | MAPK1 (0.38) | MAPK1MMP13SLC22A8 | |
| SCHEMBL6706893 | 0.80 | MAPK1 (0.45) | MAPK1MMP13SLC22A8 | |
| SCHEMBL6694916 | 0.70 | PTGER4 (0.36) | MAPK1 | |
| SCHEMBL6706838 | 0.69 | MAPK1 (0.46) | MAPK1MMP13 | |
| SCHEMBL6694967 | 0.69 | MMP13 (0.46) | MMP13SLC22A8 | |
| SCHEMBL6288756 | 0.69 | LMNA (0.42) | MAPK1 | |
| SCHEMBL6702239 | 0.65 | MMP13 (0.41) | MMP13SLC22A8 | |
| SCHEMBL6706120 | 0.64 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL6289360 | 0.64 | MMP13 (0.46) | MMP13SLC22A8 | |
| SCHEMBL6244300 | 0.64 | MMP13 (0.52) | MAPK1MMP13SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPK1 1571/4885MMP13 13/4885SLC22A8 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.